Filing Flows › Health Care › Standard Biotools (LAB)

Standard Biotools (LAB) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Standard Biotools (LAB) Q3 2026 earnings results →

Q3 2026 Revenue down 1% year over year to $19.4M · 70¢ of every $1 of revenue kept as net profit · operating margin -102.0%

Standard Biotools made $19.4M in Q3 2026 (-0.9% Y/Y): Product $14.3M, Services and Other Revenue $5.1M. Operating margin -102.0%, net earnings $13.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.

Revenue$19.4M

Year over year-0.9%

Operating margin-102.0%

Net earnings$13.5M

Operating cash flow−$6.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $19.4M in Q3 2026, down 1% year over year and down 4% from the previous quarter. Consumables was the largest line at 43% of revenue. Services and Other Revenue lost $695K year over year (down 12%), 416% of the total change.

Gross margin was 55.9%, up 7.4 points from Q3 2025. Operating costs exceeded revenue by $19.8M, an operating margin of -102.0%. Operating expenses fell 28% while revenue fell 1%. The fastest-growing cost line was Other operating costs (+23%). Net earnings were $13.5M. The effective tax rate was 0.2%. Non-operating items added $33.3M, 246% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$6.2M. Non-cash charges added back $1.2M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items used $24.6M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Nov 3, 2026	$19.4M	-0.9%	-102.0%	$13.5M	−$6.2M
Q2 2026	10-Q	Aug 5, 2026	$20.1M	-8%	-126.3%	−$26.8M	−$10.3M
Q1 2026	10-Q	May 6, 2026	$21.1M	+5%	-59.1%	$127M	−$46.6M
Q4 2025	10-K	Mar 16, 2026	$23.8M	-4%	-103.6%	$19.3M	−$1.2M
Q3 2025	10-Q	Nov 4, 2025	$19.6M	-12%	-168.5%	−$34.7M	−$22.2M
Q2 2025	10-Q	Aug 15, 2025	$21.8M	-3%	-118.1%	−$33.5M	−$20.7M
Q1 2025	10-Q	May 6, 2025	$40.8M	-10%	-80.8%	−$26.0M	−$30.3M

Charts

Latest (Q3 2026): Y/Y -1%, Q/Q -4%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income $13.5M, Operating cash flow −$6.2M.

+32.4% since FY2020: more shares outstanding (issuance, stock pay); earlier years scaled for the 4-for-1 split before FY2024.

Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.